Evofem Biosciences Inc at ROTH Conference - Fireside Chat Transcript
Good afternoon my name is Yasmeen Rahimi; I am a senior research analyst here at ROTH Capital Partners in the biotech sector. Thank you; it's really a pleasure to have Kelly Culwell, Chief Medical Officer of Evofem Biosciences. Thank you so much for being here and the format of this particular discussion is fireside chat. Feel free to interrupt us with questions.
So Kelly, thank you for being here. Can you walk us through what is your lead asset? What indication are you pursuing it for and where are you in your development stage?
Great, thank you. It's a pleasure to be here. Thanks very much for the invitation. So as Yasmeen mentioned, I am with Evofem Biosciences and our lead asset is called Amphora. It's a multipurpose vaginal pH regulator, or MVPR for short. And our primary indication is contraception, so prevention of pregnancy in women.
We have completed our Phase 3 trial and we are in the process of compiling our NDA
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |